Yoyo Cleanser Bitters and Prevention of High Fructose Diet-Induced Hyperglycemia and Hyperinsulinemia in Wistar Rats
Keywords:
High fructose diet, Yoyo cleanser bitters, blood sugar, insulin levels, HOMA-IAbstract
Background: The harmful effects of high fructose diets (HFD) on metabolic health, which includes hyperglycemia and hyperinsulinaemia, are well-documented. This study evaluates Yoyo Cleanser Bitters' efficacy in mitigating these effects induced in an animal model, by a high-fructose diet
Materials and Methods: 20 Male Wistar rats weighing between 180-220g were divided into four groups of five rats each. They were the control (normal diet), 60% High Fructose Diet (HFD) + 10% Fructose Water (FW), HFD+FW + Atorvastatin [3.52 mg/kg body weight (kg-b.w)], and HFD+FW + Yoyo cleanser bitters (3.52 ml/kg-b.w) groups. Fructose induces its deleterious effects by inducing dyslipidaemia, hence Atorvastatin was used as the standard preventive drug. After a 28-day experimental period, the rats were sacrificed and blood samples collected for fasting blood glucose (FBG) and insulin level analysis, using the glucose oxidase method, and the Enzyme linked immunosorbent assay (ELISA) technique, respectively. The Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) index was then calculated. The results were analyzed using the Statistical Package for Social Sciences (SPSS)-20 software for one-way ANOVA and Tukey’s tests.
Results: The HFD+FW group showed significantly higher (P<0.05) levels of FBG (108.60±1.9 mg/dl), insulin (10.58±0.40 µU/ml), and HOMA-IR (2.83±0.06) compared with these same parameters in the control group. Yoyo cleanser bitters prevented significantly (P<0.05), this rise in FBG (51.40±4.34 mg/dl), insulin (5.61±0.20 µU/ml), and HOMA-IR (0.71±0.07). No significant differences (P>0.05) were observed between the Control, Atorvastatin, and Yoyo cleanser bitters groups.
Conclusion: Yoyo cleanser bitters demonstrated promise in preventing high-fructose diet-induced hyperglycemia and hyperinsulinaemia in Wistar rats, suggesting its potential role in preventing HFD-induced metabolic disorders.
